TY - JOUR
T1 - Disease biomarkers in multiple sclerosis
T2 - Current serum neurofilament light chain perspectives
AU - Jakimovski, Dejan
AU - Dwyer, Michael G.
AU - Bergsland, Niels
AU - Weinstock-Guttman, Bianca
AU - Zivadinov, Robert
N1 - Funding Information:
MG Dwyer has received consultant fees from Claret Medical and EMD Serono and research grant support from Novartis. B Weinstock-Guttman received honoraria as a speaker and/or as a consultant for Biogen Idec, EMD Serono, Genentech, Novar-tis, Mallinckrodt, Celgene, Abbvie. B Weinstock-Guttman received research funds from Biogen Idec, EMD Serono, Genentech and Novartis. R Zivadinov received personal compensation from EMD Serono, Sanofi, Bristol Myers Squibb, Keystone Heart and Novar-tis for speaking and consultant fees. He received financial support for research activities from Novartis, Protembis, Bristol Myers Squibb, Keystone Heart, Mapi Pharma, V-WAVE Medical and Boston Scientific. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Publisher Copyright:
© 2021 Future Medicine Ltd.. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - The continuous neuroinflammatory and neurodegenerative pathology in multiple sclerosis (MS) results in irreversible accumulation of physical and cognitive disability. Reliable early detection of MS disease processes can aid in the diagnosis, monitoring and treatment management of MS patients. Recent assay technological advancements now allow reliable quantification of serum-based neurofilament light chain (sNfL) levels, which provide temporal information regarding the degree of neuroaxonal damage. The relationship and predictive value of sNfL with clinical and cognitive outcomes, other paraclinical measures and treatment response is reviewed. sNfL measurement is an emerging, noninvasive and disease-responsive MS biomarker that is currently utilized in research and clinical trial settings. Understanding sNfL confounders and further assay standardization will allow clinical implementation of this biomarker.
AB - The continuous neuroinflammatory and neurodegenerative pathology in multiple sclerosis (MS) results in irreversible accumulation of physical and cognitive disability. Reliable early detection of MS disease processes can aid in the diagnosis, monitoring and treatment management of MS patients. Recent assay technological advancements now allow reliable quantification of serum-based neurofilament light chain (sNfL) levels, which provide temporal information regarding the degree of neuroaxonal damage. The relationship and predictive value of sNfL with clinical and cognitive outcomes, other paraclinical measures and treatment response is reviewed. sNfL measurement is an emerging, noninvasive and disease-responsive MS biomarker that is currently utilized in research and clinical trial settings. Understanding sNfL confounders and further assay standardization will allow clinical implementation of this biomarker.
KW - clinical trials
KW - disability outcomes
KW - MRI
KW - multiple sclerosis
KW - serum neurofilament light chain
UR - http://www.scopus.com/inward/record.url?scp=85115062676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115062676&partnerID=8YFLogxK
U2 - 10.2217/nmt-2020-0058
DO - 10.2217/nmt-2020-0058
M3 - Review article
C2 - 34196596
AN - SCOPUS:85115062676
VL - 11
SP - 329
EP - 340
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
SN - 1758-2024
IS - 4
ER -